Junshi and Coherus plan to hustle the latest PD-1 to the FDA after an upbeat PhIII assessment

Paul Schloesser

Associate Editor

Four months after its first upbeat interim analysis, Shanghai’s Junshi Biosciences and California biotech Coherus BioSciences are touting a statistically significant improvement in overall survival …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Junshi and Coherus plan to hustle the latest PD-1 to the FDA after an upbeat PhIII assessment

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Jun­shi and Co­herus plan to hus­tle the lat­est PD-1 to the FDA af­ter an up­beat PhI­II as­sess­ment

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Junshi and Coherus plan to hustle the latest PD-1 to the FDA after an upbeat PhIII assessment

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify